Hybrid Blood Purification Therapy Based on Camel Nanoantibody Immunoadsorbent on Patients with Chronic Renal Failure in Nephrology Department

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td class="align_left">Group</td><td class="align_center">Concentration before experiment (pg/ml)</td><td class="align_center">Concentration after experiment (pg/ml)</td><td class="align_center">Clearance rate (%)</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td class="align_left">Control group</td><td class="align_center">296.35 ± 200.12</td><td class="align_center">248.56 ± 100.12</td><td class="align_center">16.1</td></tr><tr><td class="align_left">Experience group</td><td class="align_center">295.36 ± 231.35</td><td class="align_center">125.23 ± 115.25</td><td class="align_center">57.6</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Elimination effect of medium molecular toxin (PTH).</div>

Journal of Chemistry

tab1

Table 1

Table 1: Hybrid Blood Purification Therapy Based on Camel Nanoantibody Immunoadsorbent on Patients with Chronic Renal Failure in Nephrology Department 

Table 1 | Hybrid Blood Purification Therapy Based on Camel Nanoantibody Immunoadsorbent on Patients with Chronic Renal Failure in Nephrology Department 